Q4 2024 Earnings Call Transcript March 12, 2025 Assertio Holdings, Inc. misses on earnings expectations. Reported EPS is ...

Brendan O'Grady; Chief Executive Officer; Assertio Holdings Inc. Ajay Patel; Chief Financial Officer, Senior Vice ...

To explain a little more why I characterized 2024, as a stabilization year Assertio was coming off the acquisition and integration of Spectrum, and the subsequent loss of exclusivity of Indocin.

Assertio Holdings Inc (ASRT) reports strong Rovedon sales and strategic leadership additions, while navigating legal and competitive pressures.

Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 MillionFull Year Net Product Sales $120.8Million, Rolvedon ...

Assertio (NASDAQ:ASRT – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Monday. Separately, HC ...

Long-term use of NSAIDs has been linked to a reduced risk of developing dementia due to their anti-inflammatory properties. A ...

Indocin net product sales in the fourth quarter were $5.5 million, compared to $5.7 million in the prior quarter, reflecting pricing changes following a generic entrant late in 2023. To access the ...

Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from ...